[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361824-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-361824-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","resistance-in-lung-cancer-immunotherapy-and-how-to-overcome-it-insights-from-the-genetics-perspective-and-combination-therapies-approach","Resistance in Lung Cancer Immunotherapy and How to Overcome It - Insights from the Genetics Perspective and Combination Therapies Approach","","Lung cancer, with high incidence in Europe and Poland, remains a malignancy with very poor prognosis despite medical advances. Multiple treatment strategies depend on cancer type, molecular subtype, patient health, disease stage, and molecular profile. Immunotherapy is increasingly used alongside surgery, chemotherapy, radiotherapy, and targeted therapies, with combination approaches actively studied to improve efficacy and overcome resistance. Genetic signatures and machine learning models connect molecular patterns in the tumour microenvironment to therapy response, resistance, and metastatic potential.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/resistance-in-lung-cancer-immunotherapy-and-how-to-overcome-it-insights-from-the-genetics-perspective-and-combination-therapies-approach/361824/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/resistance-in-lung-cancer-immunotherapy-and-how-to-overcome-it-insights-from-the-genetics-perspective-and-combination-therapies-approach/361824.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What makes lung cancer prognosis difficult despite recent medical progress?","Question",{"text":62,"@type":63},"Lung cancer continues to show poor outcomes in spite of advances in medicine, with mortality closely following incidence patterns and challenging disease biology.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How does immunotherapy aim to improve lung cancer treatment and address resistance?",{"text":67,"@type":63},"Immunotherapy supports treatment by activating the immune system to attack cancer cells. Combination strategies with other therapies are actively investigated to enhance efficacy and overcome resistance.",{"name":69,"@type":60,"acceptedAnswer":70},"Which genetic and molecular signals are discussed as predictive elements for treatment response?",{"text":71,"@type":63},"The document highlights genetic signatures and molecular biomarkers such as PD-L1 expression, tumour mutation burden, immunoscore, and neoantigens as markers linked to response and resistance.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},361824,1791920391,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nResistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach  \nPaweł Zieli ´nski 1, *, Maria St˛epie ´n 2,3, Hanna Chowaniec 1, Kateryna Kalyta 4, Joanna Czerniak 1, Martyna Borowczyk 5, Ewa Dwojak 1,6, Magdalena Mroczek 7, Grzegorz Dworacki 1, Antonina ´Slubowska 8, Hanna Markiewicz 9,10, Rafał Ałtyn 11 and Paula Dobosz 1  \nAcademic Editor: RahelehRoudi  \nReceived: 11 March 2025  \nRevised: 7 April 2025  \nAccepted: 9 April 2025  \nPublished: 12 April 2025  \nCitation: Zieli ´nski, P.; St˛epie ´n, M.; Chowaniec, H.; Kalyta, K.; Czerniak, J.; Borowczyk, M.; Dwojak, E.; Mroczek, M.; Dworacki, G.; ´Slubowska, A.; et al. Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach. Cells 2025, 14, 587. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cells14080587  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Chair of Pathomorphology and Clinical Immunology, Poznan University of Medical Sciences, 61-701 Poznan, Poland; [hanna.chowaniec@gmail.com](hanna.chowaniec@gmail.com) (H.C.); [jczerniak@ump.edu.pl](jczerniak@ump.edu.pl) (J.C.); [dwojakewa@gmail.com](dwojakewa@gmail.com) (E.D.); [gdwrck@gmail.com](gdwrck@gmail.com) (G.D.); [paula.dobosz@gmail.com](paula.dobosz@gmail.com) (P.D.)  \n2 Université Paris-Saclay, UVSQ, INSERM, END-ICAP, 94805 Versailles, France; [mmaria.stepien@gmail.com](mmaria.stepien@gmail.com)  \n[3](3 Doctoral School)[ Doctoral School](3 Doctoral School), [Medical University of Lublin](Medical University of Lublin), [20-954 Lublin](20-954 Lublin), [Poland](Poland)  \n4 Faculty of Biology, University of Basel, 4123 Basel, Switzerland; [kalitakata05@gmail.com](kalitakata05@gmail.com)  \n5 Department of Endocrinology, Internal Medicine and Metabolism, Poznan University of Medical Sciences, 61-701 Poznan, Poland; [martyna.borowczyk@gmail.com](martyna.borowczyk@gmail.com)  \n6 Department of Pathomorphology, University Clinical Hospital, 61-701 Poznan, Poland  \n7 Department of Neurology, University Hospital Basel, 4123 Basel, Switzerland; [m.mroczek888@gmail.com](m.mroczek888@gmail.com)  \n8 Department of Biostatistics and Research Methodology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University of Warsaw, 02-004 Warsaw, Poland; [a.slubowska@uksw.edu.pl](a.slubowska@uksw.edu.pl)  \n9 Department of Histology and Embryology, Faculty of Medicine, Medical University of Warsaw, 02-004 Warsaw, Poland  \n10 Department of Methodology, Faculty of Medicine, Medical University of Warsaw, 02-004 Warsaw, Poland  \n11 IT Department, Poznan University of Medical Sciences, 61-701 Poznan, Poland; [rafaltyn@gmail.com](rafaltyn@gmail.com)  \n* Correspondence: [torakochirurg.zielinski@gmail.com](torakochirurg.zielinski@gmail.com)  \nAbstract: Lung cancer with the highest number of new cases diagnosed in Europe and in Poland, remains an example of malignancy with a very poor prognosis despite the recent progress in medicine. Different treatment strategies are now available for cancer therapy based on its type, molecular subtype and other factors including overall health, the stage of disease and cancer molecular profile. Immunotherapy is emerging as a potential addition to surgery, chemotherapy, radiotherapy or other targeted therapies, but also considered a mainstay therapy mode. This combination is an area of active investigation in order to enhance efficacy and overcome resistance. Due to the complexity and dynamic of cancer’s ecosystem, novel therapeutic targets and strategies need continued research into the cellular and molecular mechanis","cbCainiRNi2h8LVj","https://ap.wps.com/l/cbCainiRNi2h8LVj","pdf",1469381,32,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Epidemiology and clinical typology\n## Rationale for immunotherapy and checkpoint inhibitors","[{\"question\":\"What makes lung cancer prognosis difficult despite recent medical progress?\",\"answer\":\"Lung cancer continues to show poor outcomes in spite of advances in medicine, with mortality closely following incidence patterns and challenging disease biology.\"},{\"question\":\"How does immunotherapy aim to improve lung cancer treatment and address resistance?\",\"answer\":\"Immunotherapy supports treatment by activating the immune system to attack cancer cells. Combination strategies with other therapies are actively investigated to enhance efficacy and overcome resistance.\"},{\"question\":\"Which genetic and molecular signals are discussed as predictive elements for treatment response?\",\"answer\":\"The document highlights genetic signatures and molecular biomarkers such as PD-L1 expression, tumour mutation burden, immunoscore, and neoantigens as markers linked to response and resistance.\"}]","Resistance in Lung Cancer Immunotherapy and How to Overcome It - Insights from the Genetics Perspective and Combination Therapies Approach | PDF",1790145697,81,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f0219b05369e2ecb14665edaadc569d.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7af2e483472080c038c02823d6ab2967.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c80a90c5c7257efa5e037624f514c28.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7c5ea3d6893b6f4811f816cb2ab87bf.webp",980,1385]